But the issue with CRISPR is that it's been a slow rollout, and its business continues to incur significant losses. Is it ...

Advocates stress that while gene therapy is causing a buzz in wealthy countries, African governments must prioritise ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) reported strong Q4 results, reflecting continued execution on its broader portfolio ...

The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.

CRISPR gene therapy Casgevy can nearly eliminate sickle cell crises, but difficult stem‑cell collection is delaying access ...

Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for 2026. Click here to read now.

CRISPR Therapeutics (NasdaqGM:CRSP) reports material progress in commercializing Casgevy, the first FDA approved gene editing therapy for sickle cell disease. Reimbursement and access for Casgevy now ...

Beam Therapeutics Inc. buy thesis: base-editing gene therapy leaders, risto-cel & BEAM-302 catalysts, strong cash runway.

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, ...

The company could finally be ready to deliver on years of promise.

Cystic fibrosis (CF) specialist Vertex is tracking two newer launches that speak to its efforts to expand its prowess beyond those roots. Despite mixed early results for those rollouts so far, the ...